CEL-SCI Corporation reported new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma of the head and neck (SCCHN). The company plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) and other regulatory agencies for approval of Multikine® (Leukocyte Interleukin, Injection) in the treatment of newly diagnosed SCCHN in patients deemed at lower risk for recurrence (LR), as defined by National Comprehensive Cancer Network (NCCN) guidelines, representing a patient population of about 210,000 annual cases globally. The new data presented is very important because it focuses exclusively on the patient population (n=352) from the IT-MATTERS study for which CEL-SCI is seeking regulatory marketing approval, for locally advanced primary head and neck cancer patients scheduled to receive radiotherapy, but not chemotherapy, after surgery.

Per the NCCN guidelines, these LR patients typically are recommended to receive only radiotherapy following surgery. The recommended treatment for higher risk for recurrence (HR) patients is concurrent chemoradiotherapy (chemotherapy and radiotherapy at the same time) after surgery. In the IT-MATTERS study, 44 patients who were determined to be higher risk for recurrence following surgery should have been administered chemoradiotherapy, but received only radiotherapy, and were included in the survival analysis of the IT-MATTERS study initially performed.

A more accurate representation of the survival of the intended LR patient population treated with Multikine would have been obtained had the analysis been performed by excluding these 44 patients. At the ECHNO 2023 Congress, the company present study data demonstrating the survival and death rate advantages of the patients treated with Multikine over control in the LR population who received only radiotherapy (n=352) following surgery. Key study findings for the intended Multikine patient population who received radiotherapy, as recommended by NCCN guidelines, following surgery include: The overall survival advantage accelerated and increased over time, with the benefit of adding Multikine+CIZ to the treatment regimen as compared to Standard of Care (SOC) alone increasing from 2.8% at 3 years (36 months), to 8.3% at 4 years (48 months), to 15.6% at 5 years (60 months), with a 49.7% survival for control vs.

65.3% for the Multikine treated group at 5 years; The hazard ratio was 0.70 (95% CI: [0.49 - 1.00]) which represents a 43% survival extension; Progression free survival was 8.4% higher at 5 years for patients treated with Multikine+ CIZ+SOC as compared to patients treated with SOC control alone; 16.5% of these patients were early tumor responders, including complete tumor responders (confirmed by pathology at surgery), following the 3-week treatment with Multikine as compared to 0% responders of patients who were treated with SOC alone; Multikine patients who had an early tumor response had significantly improved survival. Their death rate was only 15.6% vs. 48.7% death rate for the control patients; Even the patients who did not have an early tumor response had a better survival than did the control group patients, with a 43.8% death rate vs.

48.7% death rate for control.